Clinical studies of liposome-encapsulated doxorubicin

Acta Oncologica

Volumn 33, Issue 7, 1994, Pages 779-786

  Gabizon, Alberto ^a,b   Isacson, Rut ^a,b   Libson, Eugene ^a,b   Kaufman, Bella ^a,b   Uziely, Beatrice ^a,b   Catane, Raphael ^a,b   Ben Dor, Cila Gera ^a,b   Rabello, Elio ^a,b   Cass, Yaacov ^a,b   Peretz, Tamar ^a,b   Sulkes, Aaron ^a,b   Chisin, Roland ^a,b   Barenholz, Yechezkel ^a,b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; LIPOSOME; MACROGOL;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY; STOMATITIS; WHOLE BODY SCINTISCANNING;

ADULT; AGED; CLINICAL TRIALS; DOXORUBICIN; DRUG CARRIERS; FEMALE; HUMANS; INDIUM RADIOISOTOPES; LIPOSOMES; MALE; MIDDLE AGED; NEOPLASMS; RADIONUCLIDE IMAGING; TISSUE DISTRIBUTION;

EID: 0028007310     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/02841869409083948     Document Type: Article

References (33)

1. Liposomal drug delivery: Current status and future prospects
2. Liposomal anthracyclines
3. Liposomes as in vivo carriers of adriamycin. Reduced cardiac uptake and preserved antitumor activity
4. Characterization. toxicity, and therapeutic efficacy of adriamycin encapsulated in liposomes
5. Pharmacological, toxicological, and therapeutic evaluation in mice of doxorubicin entrapped in cardiolipin liposomes
6. Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation
7. Reduced cardiotoxicity and nephrotoxicity with preservation of antitumor activity of doxorubicin entrapped in stable liposomes in the Lou/M Wsl rat
8. Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration
9. Systemic administration of doxorubicin-containing liposomes in cancer patients: A phase I study
10. A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin
11. Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study
12. Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes)
13. Phase I/II study of liposome-complexed mitoxantrone in patients with advanced breast cancer
14. Sterically stabilized liposomes
15. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy
16. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethyleneglycol-derivatized phospholipid: Pharmacokinetic studies in rodents and dogs
17. Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin
18. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes
19. Reporting results of cancer treatment
20. Adriamycin-containing liposomes in cancer chemotherapy
21. Liposome-associated doxorubicin: Preclinical pharmacology and exploratory clinical phase
22. Investigations on the antitumor efficacy of liposome-associated doxorubicin in murine tumor models
23. Adriamycin—A new anticancer drug with significant clinical activity
24. In vitro tests to predict in vivo performance of liposomal dosage forms
25. Liposome pharmacokinetics
26. Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients
27. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases
28. Liposomes in vivo: A relationship between stability and clearance
29. Large unilamellar liposomes with low uptake into the reticuloendothelial system
30. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors
31. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome
32. Continuous venous infusion of doxorubicin in advanced sarcomas
33. The staging of hepatic metastases arising from colorectal cancer